Introduction
Obesity with excess fat accumulation and extensively distorted metabolic regulation is a major risk factor for cardiovascular disease (CVD) (Hubert et al., 1983; Lavie et al., 2009) , type 2 diabetes (Mokdad et al., 2003) , a variety types of cancer (Carroll, 1998; Vaughan et al., 1995) and non-alcoholic fatty liver disease (NAFLD) (Wanless and Lentz, 1990) . The prevalence of NAFLD is high in developed countries (up to 30%) (Angulo, 2007; Williams, 2006) and is increasing in developing countries (nearly 10%) (Fan and Farrell, 2009 ).
Non-alcoholic steatohepatitis (NASH) is a severe form of NAFLD that includes steatosis, inflammation and fibrosis in the liver. NASH is becoming a major cause of hepatic cirrhosis and hepatocellular carcinoma (HCC). According to the "two-hit" model of NASH, two sequential injuries, lipid accumulation followed by a second insult, lead to the development of NASH. Thus, preventing the accumulation of lipids in the liver may be extremely important in the prevention of NASH (James and Day, 1998; Polyzos et al., 2009 ). Berberine (BBR), which is extracted from the roots of Rhizoma Coptidis, has been traditionally used to treat diarrhea. Interestingly, BBR decreases serum lipids in humans, hamsters, mice and rats (Chang et al., 2010; Kong et al., 2004; Wang et al., 2010; Wang et al., 2014) . BBR was also reported to be effective in the prevention and treatment of NAFLD (Chang et al., 2010; Guo et al., 2016; Yuan et al., 2015) . In a previous study using hamsters, we found that BBR was poorly absorbed into the systemic circulation but significantly accumulated in the intestine (Gu et al., 2015) . Furthermore, some studies have revealed that BBR treatment could change the composition of gut microbiota (Xie et al., 2011; Zhang et al., 2015; Zhang et al., 2012) . Therefore we hypothesized that multiple mechanisms in the This article has not been copyedited and formatted. The final version may differ from this version.
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Farnesoid X receptor (FXR, NRIH4) is a nuclear receptor that is mainly expressed in the liver, intestine, kidney and adrenals (Lee et al., 2006a; Lee et al., 2006b) . FXR is essential in maintaining bile acid homeostasis, and is important in the regulation of cholesterol metabolism (Sinal et al., 2000) . Bile acids are endogenous ligands of FXR. Intestinal, followed by hepatic, FXR signaling pathways are important for suppressing bile acid synthesis. This suppression is achieved by regulation of the expression of the Cyp7a1/CYP7A1 gene, which encodes cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in the conversion of cholesterol into bile acids (Kim et al., 2007) . FXR also regulates the expression of genes encoding various bile acid transporters, including NTCP, BSEP, MRP2, and OSTα/β in the liver and ASBT and OSTα/β in the intestine (Jung et al., 2007; Laffitte et al., 2000) . FXR has also been found to modulate triglyceride and glucose homeostasis (Potthoff et al., 2011; Trauner et al., 2010; Watanabe et al., 2004) , reduce energy expenditure (Watanabe et al., 2011) and exert anti-inflammatory and anti-fibrotic effects (Zhang et al., 2009) . However, to the best of our knowledge, the effects of BBR on intestinal FXR function have not been evaluated.
Gut microbiota, or gut flora, are bacteria that have colonized within the intestines.
Interactions between these microbiota and the human host play an important role in metabolic homeostasis and human health (Nicholson et al., 2012; Serino et al., 2009) . Bile acid metabolism is closely related to gut microbiota composition. It is well established that secondary bile acids are derived from the primary bile acids by the action of bacteria present in the intestine (Chiang, 2009 microbiota, acts on carbon-nitrogen bonds to hydrolyze taurine-or glycine-conjugated bile acids for de-conjugation (Begley et al., 2006) . BSH activity can be modulated by various antibiotics and probiotics, and this modulation may affect lipid metabolism and host health (Li et al., 2013; Smet et al., 1995; Smet et al., 1998) .
As shown in our previous study, BBR enhanced the production of bile acids in hamsters.
Moreover, CYP7A1 and CYP27A1 mRNA and protein expression was induced by BBR in a concentration-dependent manner (Gu et al., 2015) . In the current study, we have used wild type (WT) and intestine-specific FXR knockout (FXR int-/-) mice to evaluate the regulatory effects of BBR on BSH activity and bile acid turnover, with the purpose of gaining insight into the anti-obesity and lipid-lowering mechanisms of BBR.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods

Chemicals and reagents
BBR (≥98%) was purchased from Nanjing Zelang Medical Technology Co., Ltd. (Nanjing, China). CDCA, UDCA and HDCA were purchased from the National Institutes for Food and Drug Control (Beijing, China). CA, DCA, TCA, LCA, GCDCA, GCA, TCDCA, TDCA, d4-CA, Triton X-114 and tert-Butanol were purchased from Sigma-Aldrich (St Louis, MO, USA), d4-TCA and d4-GCA were purchased from TLC PharmaChem (Concord, ON, Canada). 
Animal treatment
WT and FXR int-/-mice with a C57BL/6J background (6 to 8 weeks old, male) were bred and maintained at Rutgers, the State University of New Jersey (Kong et al., 2012) . All animals were housed under specific-pathogen-free conditions, fed ad libitum and maintained under a 12-hour light-dark cycle. All animal experiments were performed with approval from the Institutional Animal Care and Use Committee (IACUC) of Rutgers University and from the Animal Ethics Committee of China Pharmaceutical University.
To determine the effects of BBR on the hepatic accumulation of triglycerides and its anti-obesity activity, four groups of WT mice were used. were fed with the AIN-93M or HFD. Groups were paired and intragastrically administered either CMC-Na as a vehicle control (n=4) or BBR (150 mg/Kg, n=4) for 8 weeks. BBR was grounded into fine particles and passed through a sieve of 120 meshes. The powder was then stirred and suspended with 0.5% CMC-Na aqueous solution to achieve a final concentration of 15 mg/mL. This suspension was given to mice by oral gavage at a dose of 10 mL/Kg body weight. The body weights of the mice were recorded every week. The animals were fasted overnight before euthanasia. At the time of euthanasia, the mice were anaesthetized by xylazine-ketamine and avertin, and samples of blood, liver, gallbladder, small intestine and cecal content were collected and stored at -80°C for further analysis.
For the taurocholic acid (TCA) treatment, WT mice (6 weeks old, male) were provided by Yangzhou University, China. Two groups (n=6) of mice were intragastrically administered with either vehicle (saline) or 100 mg/Kg TCA for 7 days. Tissue collection was performed as described above.
Oral glucose tolerance test (OGTT)
7 weeks after treatment with BBR, OGTT was performed, mice were fasted for 6 hrs (9:00 a.m. to 3:00 p.m.) and oral administrated with 1 g/Kg glucose. Blood was drawn at 0, 15, 30, 60, 90 and 120 mins after administration and blood glucose was measured by Contour TS blood glucose meter (Bayer HealthCare LLC, Mishawaka, IN). Area under the curve (AUC) was calculated.
Measurement of hepatic total triglycerides
This article has not been copyedited and formatted. The final version may differ from this version. To further evaluate the lipid-lowering effect of BBR, hepatic total triglycerides were measured. Briefly, a 100-mg sample of liver was homogenized with 1 mL of Buffer I (18 mM Tris HCl pH=7.5, 300 mM Mannitol, 50 mM EGTA and 0.1 mM PMSF), and 400 μ L of homogenate was extracted with 2 mL of chloroform: methanol mixture (2:1). After overnight mixing, 1 mL of water was added to each tube and mixed, followed by centrifugation at 3000 g for 5 min, afterwards the lower lipid phase was collected and concentrated using a according to the protocol provided.
Oil-Red-O staining
Livers were frozen in optimal cutting temperature compound (O.C.T.) during tissue collection, sectioned into 8-µM-thick slices and stained with Oil-Red-O using a previously described protocol (Kong et al., 2009 ).
qRT-PCR analysis
Total RNA was isolated using TRI Reagent (Sigma). The mRNA concentration was quantified using a Nano Drop ND-1000 spectrophotometer (Thermo Scientific). The diluted mRNA (0.5 μ g/μL) was reverse-transcribed according to the manufacture's protocol, and the gene expression levels were determined by SYBR-green-based real-time-PCR technique (ABI ViiA MOL #106617
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Western blot
Total protein in the liver was extracted and western blot analysis was performed as previously described (Cao et al., 2013; Kong et al., 2012) . Antibodies against p-ERK1/2 and T-ERK1/2
were purchased from Cell Signaling Technology, Inc. (Beverly, MA, US), antibodies against CD36 and GAPDH (the loading control) were purchased from Wuhan Boster Biological Technology Co., Ltd. (Wuhan, China). The intensity of bands on the Western blots was quantified by Image Lab statistical software (Bio-Rad Laboratories, Hercules, CA, US).
Determination of bile acid composition in serum, intestine and feces
Bile acids in serum, liver, intestine and feces were analyzed by LC-MS/MS as previously reported with some revisions (Zhou et al., 2014) . Briefly, bile acids were extracted with 70%
ethanol at 55°C for 4 hrs, and then subjected to solid-phase extraction using solid-phase extraction technique (UCT-CLEAN UP C18, Oasis-HLB and Oasis-MAX cartridges). The resultant residue was re-dissolved in 100 μ L of methanol and centrifuged at 18,000 rpm for 10 mins. Chromatography was performed on a Shimadzu HPLC system (Kyoto, Japan) coupled to an AB SCIEX 4000 mass spectrometer (AB Sciex). A Waters Atlantis T3 column (2.1×100 mm, 3 μ m) protected by a Security Guard (Phenomenex Inc., CA, USA) was used for chromatographic separation. The mobile phase consisted of 0.1% formic acid in water and methanol. Cholic-2,2,4,4-D4 acid (d4-CA) and glycocholic-2,2,4,4-D4 (d4-GCA) acid were used as internal standards.
Measurement of BSH activity
After 8 weeks of treatment, the cecal contents of mice were recovered and pooled in sterile tubes. The gut contents were boiled with an aqueous solution containing 20% glycerol and 1.8%
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All experimental procedures were performed in a sterile environment.
Gut flora were diluted 10-fold in a peptone-yeast extract (PY) medium prepared as previously described (Zhao et al., 2013) To analyze the gut contents of the mice fed with the control diet or the HFD, BBR was added into PY medium at concentrations of 0 and 100 μ g/mL. Following this, the gut flora were diluted in PY medium by 10-fold and then cultured at 37°C and 200 rpm for 12 hrs to allow anaerobic bacteria to proliferate. The following procedure was the same as previously described, and the production of d4-CA was determined by LC-MS/MS.
Statistical Analysis
All data were expressed as mean ± SD. Differences among groups were tested by one-way ANOVA and/or two-tailed Student's t tests. Heatmap was constructed using the R package pheatmap (http://cran.r-project.org/web/packages/pheatmap/index.html).
Results
BBR prevented diet-induced obesity and triglyceride accumulation in the liver
To investigate the anti-obesity and lipid-lowering effects of BBR, the body weight of mice were recorded weekly. After 8 weeks, the mice fed the HFD showed a significant increase in body weight (31.03±1.82 g vs. 27.57±0.9 g, P<0.001), while treatment with BBR reduced this effect (25.33±1.76 g vs. 31.03±1.82 g, P<0.001) (Fig. 1A) . To explore the effect of BBR on glucose homoeostasis, OGTT was performed and the results revealed that after 7 weeks of HFD, compared with vehicle groups, mice treated with BBR displayed significantly reduced blood glucose levels after glucose loading, suggesting improved insulin sensitivity. For mice fed with AIN-93M, there was no change (Fig. 1B and 1C) . Moreover, fasting serum glucose levels from BBR-treated groups decreased significantly (Fig. 1D ). Triglyceride levels in serum and livers of mice fed with HFD were significantly increased by 1.2 fold and 4.4 fold, respectively. After BBR treatment, there was a significant decrease in serum and hepatic triglycerides by 19% and 47%, respectively ( Fig. 1E and 1F ). Lipid droplets in the liver also appeared to be reduced in size revealed by Oil-Red-O staining (Fig. 1G) .
BBR activated the intestinal FXR pathway and reduced CD36 gene expression in liver
For genes involved in fatty acid metabolism and transportation, the expression of Fas was decreased by BBR treatment, and the expression of Cyp4a10 was upregulated significantly.
The expression of Mtp and ApoB were not changed ( Fig. 2A and 2B ). up-regulation of Fgf15 and Ibabp mRNA levels in the distal ileum (Fig. 2C, 2D , 2E and 2F).
Furthermore, oral administration of BBR reduced Cyp7a1 mRNA levels in mice (Fig. 2D) , which is consistent with the up-regulation of intestinal Fgf15. Because CD36 is critical to the uptake of long-chain fatty acids into the liver and has been shown to be reduced by FXR activation, we also examined its mRNA expression and protein level. We found that treatment with BBR markedly down-regulated the mRNA expression of CD36 in the liver by approximately 48% (P=0.045, Fig. 2B ). The protein level of CD36 was also reduced by BBR treatment ( Fig. 2E and 2F ).
BBR treatment caused modifications in bile acid composition
Bile acid composition is an indicator of the homeostasis and turnover of cholesterol as well as of bile acid metabolism activity. There is species difference in bile acid composition and muricholic acid (MCA) only exists in rodent. In mice, with respect to individual bile acid, TCA and TβMCA were agonist and antagonist of FXR, respectively (Sayin et al., 2013) .
Therefore, we measured bile acid profiles in serum, liver, intestine and feces using LC-MS/MS. The composition of bile acids was shown in Fig. 3A , 4A, 5A and 6A.
In serum, HFD increased the levels of GCA, TCA and TUDCA, whereas decreased the levels of other bile acids. Treatment of BBR increased the levels of TCA and LCA, but decreased the levels of other bile acids (Fig. 3A) . Specifically, for TβMCA and TCA, we found that the consumption of the HFD did not change TCA levels, whereas TβMCA levels increased in serum. Treatment of BBR reduced TβMCA in the serum of mice fed with both AIN-93M and HFD. For TCA, treatment of BBR had no influence on mice fed with AIN-93M, but significantly increased TCA level in serum of mice fed with HFD ( Fig. 3B and 3C ).
This article has not been copyedited and formatted. The final version may differ from this version. For bile acids in the liver, the consumption of the HFD did not change the levels of bile acids significantly. Treatment of BBR increased the level of TUDCA, TDCA, LCA and TCA, but not the levels of GCA and CA. The rest of bile acids trended towards reduction (Fig. 4A) .
Specifically, for TβMCA and TCA, treatment with BBR decreased TβMCA levels in mice fed with both diets, and BBR also decreased TCA levels in mice fed with AIN-93M, whereas there was no obvious change for TCA in mice fed with the HFD (Fig. 4B and 4C ).
In the intestine, HFD rarely changed the levels of individual bile acids. BBR also had no effect on THDCA, LCA and GCA; however, the levels of UDCA, α
CA, CDCA, HDCA and DCA were decreased. The levels of TDCA, TCDCA and TUDCA showed a trend of increase (Fig. 5A) . Specifically, for TβMCA and TCA, BBR showed rare regulation effect on TβMCA. TCA levels were both elevated after treated with BBR ( Fig. 5B and 5C).
With respect to bile acid composition in the feces, the consumption of a HFD increased TDCA, α
MCA, ω
MCA, β
MCA, TCDCA, TLCA, CDCA, DCA, LCA, UDCA and HDCA levels (Fig. 6A) . Specifically, both TβMCA (Fig. 6B) and TCA (Fig. 6C ) levels were increased after the consumption of the HFD and were even further elevated after treatment with BBR.
BBR inhibited BSH activity
BSH activity is critically involved in the capacity of gut microbiota to hydrolyze conjugated bile acids. A previously established in vitro metabolism system was used to evaluate the BSH activity of gut microbiota (Zhao et al., 2013) . Overall, a decrease in d4-TCA level was found, and d4-CA production is a measure of BSH activity (Fig. 7A) . Relative to the gut microbiota This article has not been copyedited and formatted. The final version may differ from this version. of the mice that were fed the control diet, d4-TCA was hydrolyzed at a slower rate and there was less of an increase of d4-CA in the mice fed the HFD. Moreover, treatment with BBR reduced the hydrolyzation of d4-TCA and reduced d4-CA to undetectable levels, indicating a marked decrease in the production of d4-CA. Accordantly, co-incubation of BBR (100 μ g/mL)
in vitro also showed an inhibition of BSH activity for gut microbiota from mice fed with both control diet and HFD ( Fig. 7B and 7C ).
TCA activated the intestinal FXR pathway and reduced Cd36 expression in the liver
BBR treatment decreased BSH activity and increased the levels of TCA in the small intestine (Fig. 5E ). Therefore, we determined the effects of a 7-day TCA treatment on FXR signaling pathway. After TCA treatment, hepatic FXR target gene, Shp, and intestinal FXR target genes, Fgf15 and Ibabp mRNA levels were up-regulated ( Fig. 8A and 8B ). The expression of Fas was decreased and the expression of Cyp4a10 was increased significantly (Fig. 8C) .
Consistent with the effects of BBR treatment, in the liver, ERK1/2 phosphorylation was activated and the Cyp7a1 mRNA levels were significantly reduced, the mRNA expression and protein level of CD36 were both reduced (Fig. 8A, 8D , 8E and 8F).
Anti-obesity and lipid-lowering effects of BBR was diminished in FXR int-/-mice
To confirm the role of the intestinal FXR signaling pathway in the lipid-lowering effect of BBR, FXR int-/-mice were used. The data showed that BBR treatment did not change either the body weights or the serum triglyceride levels of FXR int-/-mice that were fed with HFD ( Fig.   9A and 9B). Measurement of lipids and Oil-Red-O staining showed that triglycerides in the livers were not affected by BBR treatment as well ( Fig. 9C and 9D ). Fas, Mtp and ApoB, was not changed significantly by BBR treatment, Cyp4a10 was induced (P=0.049) ( Fig. 10A and 10B) . In contrast to an increasing trend of intestinal mRNA levels of Fgf15 that were observed, the mRNA levels of Ibabp and Ostβ were significantly reduced, which is an opposite trend from that observed in WT mice (Fig. 10C) . Moreover, the expression of the genes encoding Cyp7a1 (P=0.005) and Cd36 (not significantly) was increased after BBR treatment ( Fig. 10B and 10D ). These results indicate that the lipid-lowering effect of BBR relies on an intact intestinal FXR signaling pathway, and regulation of Cd36 expression by increased Fgf15 signaling in the liver might be the key mechanism.
Discussion
Anti-obesity and lipid-lowering effects of orally administered BBR
BBR is reported to possess anti-obesity and lipid-lowering effects in different species, and previous studies suggest that the lipid-lowering mechanisms exerted by BBR include the up-regulation of LDLR and the activation of the AMPK pathway (Brusq et al., 2006; Kong et al., 2004) . Other studies have reported that BBR can ameliorate NAFLD by modulating hepatic mRNA and lncRNA expression profiles (Yuan et al., 2015) . However, the activation of AMPK was not observed in an in vivo study (Guo et al., 2016) . In addition, the in vitro concentrations of BBR used in the referenced studies were two orders of magnitude higher than the blood concentrations achieved following the oral administration, and when BBR was present in the liver at low concentrations, it failed to produce pharmacological effects (Kong et al., 2004; Liu et al., 2010) . In contrast, high levels of BBR accumulate in the This article has not been copyedited and formatted. The final version may differ from this version. gastrointestinal tract after the oral administration. Therefore, we hypothesized that the pharmacological effects of orally administered BBR exert through BBR-mediated modulation of intestinal microbiota. We first tested this hypothesis in the WT mice. We found that BBR indeed exerted an anti-obesity effect, improved insulin resistance and ameliorated the accumulation of triglycerides in the liver (Fig. 1) . Moreover, we hypothesized the intestinal, but not hepatic FXR signaling pathway was involved in these beneficial effects ( Fig. 2C and   2D ).
Intestinal FXR plays a pivotal role in the pharmacological effects of BBR
The intestinal FXR signaling pathway plays an important role in the development of NAFLD.
It has been documented that FXR agonists inhibit inflammation, repress macrophage activation, reduce adipose differentiation-related protein levels, increase cholesteryl ester transfer protein expression, reduce Cd36 gene expression and promote the conversion of adipose tissue from white adipose tissue (WAT) to brown adipose tissue (BAT). These actions reduce obesity and improve insulin resistance (Fang et al., 2015; Ma et al., 2013; Yao et al., 2014; Zhang et al., 2009) . As the intestinal FXR signaling pathway appeared to be activated in WT mice following treatment with BBR ( Fig. 2C) , FXR int-/-mice were used to further test the role of intestinal FXR in the pharmacological effects of BBR. We found that BBR did not produce anti-obesity and lipid-lowering effects in FXR int-/-mice (Fig. 9) , which further suggests that intestinal FXR may be the critical mediator of the pharmacological effects of BBR.
According to previous tissue distribution studies that in the liver and small intestine the concentration of BBR is approximately 100 ng/g tissue (Hu et al., 2014; Tan et al., 2013) . Due
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BBR modulated bile acid composition and BSH activity
It is well known that different bile acids differentially regulate the activity of FXR, and the modulation of FXR activity by endogenous bile acids creates complicated and comprehensive effects. CDCA, CA and TCA are endogenous agonists of FXR (Makishima et al., 1999; Parks et al., 1999) , whereas ursodeoxycholic acid (UDCA) (Mueller et al., 2015) and TβMCA (Li et al., 2013; Sayin et al., 2013) are endogenous antagonists of FXR. We measured the compositions of bile acids in the sera and feces of mice treated with BBR. In the sera of the mice that were treated with BBR, the majority of conjugated bile acids, especially TCA, were present at elevated levels, whereas the level of TβMCA was unchanged, and the majority of unconjugated bile acids were present at reduced levels. A similar phenomenon was also observed in the feces, in which tauro-conjugated bile acid levels increased following BBR treatment. Bile acid metabolism is closely related with gut microbiota composition; therefore, the modulation of gut microbiota should be considered in the context of BBR treatment.
Both obesity and NAFLD are considered to be closely related to changes in gut microbiota composition, indicating the importance in modulation of gut microbiota (Abu-Shanab and Quigley, 2010; Compare et al., 2012; Musso et al., 2011; Nicholson et al., 2012; Tremaroli and Bäckhed, 2012) . BSH, an enzyme produced by gut microbiota, serves as exogenous BSH in mouse intestines or treatment with probiotics can significantly reduce weight gain and plasma and liver lipids, as well as improve insulin resistance (Degirolamo et al., 2014; Joyce et al., 2014 ). In the current study, we found that BBR significantly inhibited BSH activity both in vivo and in vitro, and the levels of tauro-conjugated bile acids, especially TCA, became substantially elevated following the inhibition of BSH activity. However, BSH has been found to be expressed by all major bacterial divisions and archaeal species in the gut based on metagenomic analyses (Jones et al., 2008) , and BBR was found to reduce the proportions of both fecal Firmicutes and fecal Bacteroidetes in HFD-fed mice (Xie et al., 2011) . Based on these findings, the modulation of BSH activity by BBR may be due to an indiscriminant inhibition of gut microbiota.
Reduction of Cd36 expression ameliorated hepatic lipid accumulation
The activation of the intestinal FXR signaling pathway induces the expression of Fgf15
(human homologue, Fgf19), which acts on the liver and inhibits the expression of Cd36.
CD36 (cluster of differentiation 36), also known as FAT (fatty acid translocase), belongs to the class B scavenger receptor family, which includes receptors for selective cholesteryl ester uptake and is important for lipid transportation and metabolism (Bieghs et al., 2010; Febbraio et al., 2001) . The FXR agonist GW4064 showed an inhibitory effect on Cd36 expression and reduced the accumulation of triglycerides in the liver without affecting expression of genes that are directly involved in lipogenesis (Ma et al., 2013) . Furthermore, the treatment of FXR knockout mice with FGF19 protein reduced liver expression of Cd36, reduced the transportation of free fatty acids and inhibited the synthesis of triglycerides (Miyata et al., 2011) .
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In summary, in mice fed with HFD, BBR shows anti-obesity and lipid-lowering effects in TβMCA levels in the liver. C. TCA levels in the liver. Error bars show SD of replicates (n=6). *, P < 0.05, **, P < 0.01, ***, P < 0.001, compared with normal control group; #, P < 0.05, compared with high fat control group. This article has not been copyedited and formatted. The final version may differ from this version. TβMCA levels in the intestine. C. TCA levels in the intestine. Error bars show SD of replicates (n=6). **, P < 0.01, compared with normal control group; #, P < 0.05, compared with high fat control group. Total RNA were isolated form the liver and intestine from male FXR int-/-mice after treatment This article has not been copyedited and formatted. The final version may differ from this version. 
